Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer
Authors:
- Hal W. HirteHHHal W. Hirte
- Laurie ElitLELaurie Elit
- Russel J. SchilderRSRussel J. Schilder
- Lisa WangLWLisa Wang
- Katrina MacAlpineKMKatrina MacAlpine
- John J. WrightJWJohn J. Wright
- Amit M. OzaAOAmit M. Oza
- 1 June 2010
- journal article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 20 (5) , 787-793
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortiaGynecologic Oncology, 2008
- Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous CancerJournal of Clinical Oncology, 2007
- Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic CancerClinical Cancer Research, 2006
- The Myth of Measurable Disease in Ovarian CancerJournal of Clinical Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Phase II study of gemcitabine in previously platinum-treated ovarian cancer patientsAnti-Cancer Drugs, 1995
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989